BlackRock’s Merrimack Pharmaceuticals, Inc. MACK Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q2 | – | Sell |
-723,294
| Closed | -$10.7M | – | 5448 |
|
|
2024
Q1 | $10.7M | Sell |
723,294
-20,329
| -3% | -$286K | ﹤0.01% | 3321 |
|
|
2023
Q4 | $9.97M | Buy |
743,623
+52,806
| +8% | +$667K | ﹤0.01% | 3400 |
|
|
2023
Q3 | $8.52M | Buy |
690,817
+14,527
| +2% | +$176K | ﹤0.01% | 3430 |
|
|
2023
Q2 | $8.32M | Buy |
676,290
+454,037
| +204% | +$5.68M | ﹤0.01% | 3497 |
|
|
2023
Q1 | $2.73M | Buy |
222,253
+12,495
| +6% | +$147K | ﹤0.01% | 3905 |
|
|
2022
Q4 | $2.4M | Buy |
209,758
+2,975
| +1% | +$24.5K | ﹤0.01% | 4060 |
|
|
2022
Q3 | $775K | Sell |
206,783
-932
| -0.4% | -$4.3K | ﹤0.01% | 4575 |
|
|
2022
Q2 | $1.24M | Sell |
207,715
-3,724
| -2% | -$21K | ﹤0.01% | 4449 |
|
|
2022
Q1 | $1.34M | Sell |
211,439
-1,224
| -0.6% | -$6.88K | ﹤0.01% | 4560 |
|
|
2021
Q4 | $832K | Buy |
212,663
+1,612
| +0.8% | +$7K | ﹤0.01% | 4728 |
|
|
2021
Q3 | $1.02M | Buy |
211,051
+23,961
| +13% | +$125K | ﹤0.01% | 4547 |
|
|
2021
Q2 | $1.2M | Sell |
187,090
-68,413
| -27% | -$452K | ﹤0.01% | 4459 |
|
|
2021
Q1 | $1.6M | Buy |
255,503
+3,572
| +1% | +$25.5K | ﹤0.01% | 4362 |
|
|
2020
Q4 | $1.74M | Sell |
251,931
-849
| -0.3% | -$4.19K | ﹤0.01% | 4083 |
|
|
2020
Q3 | $1.01M | Buy |
252,780
+1,846
| +0.7% | +$6.78K | ﹤0.01% | 4109 |
|
|
2020
Q2 | $836K | Buy |
250,934
+3,012
| +1% | +$10.3K | ﹤0.01% | 4087 |
|
|
2020
Q1 | $533K | Sell |
247,922
-771
| -0.3% | -$2.25K | ﹤0.01% | 4038 |
|
|
2019
Q4 | $783K | Sell |
248,693
-169
| -0.1% | -$677 | ﹤0.01% | 4067 |
|
|
2019
Q3 | $1.12M | Sell |
248,862
-69,512
| -22% | -$347K | ﹤0.01% | 3940 |
|
|
2019
Q2 | $1.51M | Sell |
318,374
-5,516
| -2% | -$26.1K | ﹤0.01% | 3875 |
|
|
2019
Q1 | $1.77M | Sell |
323,890
-1,708
| -0.5% | -$7.85K | ﹤0.01% | 3748 |
|
|
2018
Q4 | $989K | Buy |
325,598
+2,487
| +0.8% | +$8.63K | ﹤0.01% | 3892 |
|
|
2018
Q3 | $1.35M | Buy |
323,111
+2,064
| +0.6% | +$8.7K | ﹤0.01% | 3874 |
|
|
2018
Q2 | $1.24M | Sell |
321,047
-702,515
| -69% | -$4.66M | ﹤0.01% | 3877 |
|
|
2018
Q1 | $6.48M | Sell |
1,023,562
-9,813
| -0.9% | -$81.2K | ﹤0.01% | 3313 |
|
|
2017
Q4 | $8.33M | Sell |
1,033,375
-280,834
| -21% | -$2.62M | ﹤0.01% | 3241 |
|
|
2017
Q3 | $15M | Buy |
1,314,209
+24,369
| +2% | +$256K | ﹤0.01% | 2946 |
|
|
2017
Q2 | $12.6M | Sell |
1,289,840
-180,970
| -12% | -$3.7M | ﹤0.01% | 3043 |
|
|
2017
Q1 | $35.6M | Buy |
1,470,810
+1,468,590
| +66,153% | +$36.7M | ﹤0.01% | 2426 |
|
|
2016
Q4 | $71K | Sell |
2,220
-2,208
| -50% | -$94.2K | ﹤0.01% | 2755 |
|
|
2016
Q3 | $221K | Buy |
4,428
+885
| +25% | +$36.7K | ﹤0.01% | 2096 |
|
|
2016
Q2 | $151K | Buy |
3,543
+2,542
| +254% | +$138K | ﹤0.01% | 2266 |
|
|
2016
Q1 | $66K | Buy |
1,001
+565
| +130% | +$29.5K | ﹤0.01% | 2222 |
|
|
2015
Q4 | $27K | Buy |
436
+24
| +6% | +$1.69K | ﹤0.01% | 2425 |
|
|
2015
Q3 | $28K | Buy |
412
+54
| +15% | +$4.41K | ﹤0.01% | 2201 |
|
|
2015
Q2 | $35K | Buy |
358
+9
| +3% | +$856 | ﹤0.01% | 2139 |
|
|
2015
Q1 | $33K | Sell |
349
-72
| -17% | -$6.13K | ﹤0.01% | 2137 |
|
|
2014
Q4 | $38K | Hold |
421
| – | – | ﹤0.01% | 2089 |
|
|
2014
Q3 | $29K | Hold |
421
| – | – | ﹤0.01% | 2171 |
|
|
2014
Q2 | $25K | Sell |
421
-58
| -12% | -$2.94K | ﹤0.01% | 2274 |
|
|
2014
Q1 | $19K | Hold |
479
| – | – | ﹤0.01% | 2394 |
|
|
2013
Q4 | $21K | Hold |
479
| – | – | ﹤0.01% | 2351 |
|
|
2013
Q3 | $14K | Buy |
479
+49
| +11% | +$1.71K | ﹤0.01% | 2465 |
|
|
2013
Q2 | $23K | Buy |
+430
| New | +$18.8K | ﹤0.01% | 2244 |
|
Other funds holding MACK
RA
JC
BlackRock's MACK Position: Q2 2024 in Review
BlackRock sold out of Merrimack Pharmaceuticals, Inc. (MACK) in Q2 2024, closing a stake of 723,294 shares — an estimated $10.7M sold.
BlackRock first reported a position in MACK in Q2 2013 and held it in 44 quarters. The position peaked at $35.6M in Q1 2017. 12 funds tracked by Wall St. Rank hold MACK as of Q2 2024.
- BlackRock reported no remaining Merrimack Pharmaceuticals, Inc. position as of Q2 2024 after selling out during the quarter.
- BlackRock sold 723,294 Merrimack Pharmaceuticals, Inc. shares in Q2 2024, an estimated $10.7M.
- BlackRock first reported a position in Merrimack Pharmaceuticals, Inc. in Q2 2013 and held it in 44 quarters.
- BlackRock's Merrimack Pharmaceuticals, Inc. position peaked at $35.6M in Q1 2017.
- 12 funds tracked by Wall St. Rank held Merrimack Pharmaceuticals, Inc. as of Q2 2024.
Based on BlackRock's 13F filing for Q2 2024, filed 13 Aug 2024.